Mgr. Miroslav Boudný, Ph.D.
Junior researcher, Marek Mráz Research Group
Office: bldg. E35/281
Kamenice 753/5
625 00 Brno
Phone: | +420 549 49 7500 |
---|---|
E‑mail: |
Total number of publications: 22
2021
-
The biology of miRNAs in B cell malignancies and their use as biomarkers.
Year: 2021, type: Conference abstract
-
The role of long non-coding RNAs in the BCR-mediated activation of malignant B cells.
Year: 2021, type: Conference abstract
2020
-
ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias
CANCER TREATMENT REVIEWS, year: 2020, volume: 88, edition: AUG, DOI
-
The Important Role of STAT3 in Chronic Lymphocytic Leukaemia Biology
Klinická onkologie, year: 2020, volume: 33, edition: 1, DOI
2019
-
ATR-CHK1 signaling is active and targetable in quiescent CLL cells
Year: 2019, type: Conference abstract
-
Cytogenetická a molekulárně biologická analýza genu a proteinu Myc u pacientů s chronickou lymfocytární leukémií.
Year: 2019, type: Conference abstract
-
Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells
Haematologica, year: 2019, volume: 104, edition: 12, DOI
2018
-
Inovativní inhibitor proteinu CHK1 indukuje apoptózu u buněk chronické lymfocytární leukémie s mutacemi v genu TP53
Year: 2018, type: Conference abstract
-
Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations
Year: 2018, type: Conference abstract
2017
-
ATR-Chk1 pathway as a therapeutic target for leukemia and lymphoma
Year: 2017, type: Conference abstract